Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NVS vs JNJ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

JNJ Captures Overall Composite Edge (43.8 HOLD vs 41.5 SELL), While NVS Leads 3–2 on Growth & Valuation Pillars

JNJ Overall Winner 6-Pillar Tally: NVS 3 – 2 JNJ (1 Tie) Matrix Metrics: NVS 5 – 5 JNJ

As of Nov 16, 2026, Johnson & Johnson (JNJ) captures the overall head-to-head institutional edge over Novartis AG (NVS) on higher Unified Composite conviction (43.8/100 HOLD vs. 41.5/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while NVS wins 3–2 across the 6-pillar growth and valuation breakdown. NVS trades at $161.59 (16.2x Forward P/E, 34.0% operating margin) versus JNJ at $284.71 (24.6x Forward P/E, 26.6% operating margin).

  • Growth vs. Quality Trade-Off: JNJ earns the overall head-to-head edge with a stronger Unified Composite Score (43.8/100 HOLD vs. NVS 41.5/100 SELL) and -0.06β · 25% Vol risk profile, whereas NVS leads top-line expansion (+4.7% YoY revenue growth, 3.81x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVS vs JNJ
NVS NYSE
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
TTM Revenue $40.5B
Forward P/E 16.2x
Beta / 30D Vol 0.31β · 27% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 61
RSI-14: 60.8 · SMA20: $159.19 · SMA50: $149.17
JNJ NYSE Head-to-Head Winner
Johnson & Johnson
Pharmaceutical Preparations
$284.71
-0.36% 1D
Market Cap $682.5B
TTM Revenue $99.3B
Forward P/E 24.6x
Beta / 30D Vol -0.06β · 25% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 10.0 Fund 48.0 Flow 66.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 65
RSI-14: 64.8 · SMA20: $273.12 · SMA50: $267.06

6-Pillar Scorecard Institutional Category Breakdown (NVS 3 – 2 JNJ)

Columns: Metric · NVS · JNJ
1. Valuation Multiples NVS
Forward P/E 16.2x 24.6x
Trailing P/E 30.6x 43.0x
PEG Ratio 3.81x 3.16x
EV / Revenue 7.5x 7.2x
2. Growth & Scale JNJ
Revenue Growth (YoY) +4.7% +5.9%
Earnings Growth (YoY) -68.8% -95.9%
TTM Revenue (USD) $40.5B $99.3B
Market Cap $302.9B $682.5B
3. Profitability & Quality NVS
Gross Margin 75.2% 67.8%
Operating Margin 34.0% 26.6%
Net Profit Margin 17.5% 16.2%
Return on Equity (ROE) 24.3% 20.0%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $17.0B EBITDA $19.6B
Cash Flow Margin 42.0% EBITDA Mgn 19.7%
Net Cash / Leverage $19.71 Book/Sh · 24.3% ROE $27.7B Net Debt (0.55x D/E)
Dividend Yield 2.96% 1.88%
5. Options & Positioning JNJ
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 16.9% (6th %ile) 25.7% (28th %ile)
Put/Call OI Skew Thin ADR Chain 0.76x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity 41.2% of Rev ($16.7B) 41.2% of Rev ($40.9B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - General Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVS (5) vs JNJ (5)
Institutional Metric NVS JNJ Criterion Row Edge
Market Capitalization
Scale
$302.9B $682.5B Larger Scale JNJ
Trailing P/E Ratio
Valuation
30.6x 43.0x Lower Multiple NVS
Forward P/E Ratio
Valuation
16.2x 24.6x Lower Multiple NVS
Revenue Growth (YoY)
Growth
+4.7% +5.9% Higher Growth JNJ
Operating Margin (TTM)
Profitability
34.0% 26.6% Higher Margin NVS
Net Profit Margin
Profitability
17.5% 16.2% Higher Margin NVS
Return on Equity (ROE)
Capital Efficiency
24.3% 20.0% Higher ROE NVS
52-Week Range Position
Momentum
81% ($123–$170) 94% ($193–$290) Stronger Trend JNJ
Beta / 30D Volatility
Risk Regime
0.31β · 27% Vol -0.06β · 25% Vol Lower Realized Risk JNJ
Unified Institutional Score
Composite Signal
41.5 / 100 (SELL) 43.8 / 100 (HOLD) Higher Composite JNJ
Trailing 12M Revenue (USD)
Operating Scale
$40.5B $99.3B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% 67.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.81x PEG · 7.5x EV/Rev 3.16x PEG · 7.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) $19.6B ($27.7B Net Debt (0.55x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon JNJ +4.13 pp
NVS: +7.28% · JNJ: +11.41%
3M Horizon JNJ +0.46 pp
NVS: +4.56% · JNJ: +5.02%
6M Horizon JNJ +16.03 pp
NVS: +8.34% · JNJ: +24.37%
1Y Horizon JNJ +23.32 pp
NVS: +22.5% · JNJ: +45.82%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs JNJ. Trailing 12-month operating profitability (NVS 34.0% vs JNJ 26.6%) and valuation multiples (NVS 16.2x vs JNJ 24.6x Forward P/E) are benchmarked directly in Pillar 4 below.

NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.2x
JNJ ADR TTM Benchmark FX-Normalized USD
TTM Revenue$99.3B
Gross Margin67.8%
Op. Margin26.6%
ROE / Fwd P/E20.0% · 24.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
JNJ CONSOLIDATION
61d in phase · OBV ACCUMULATION
Current IV 25.7%
IV Percentile 28th %ile
Put/Call OI Skew 0.76x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact JNJ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published
JNJ Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $682.5B market capitalization and 26.6% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($40.9B)
90D Engineering Disclosures 0 Published

Investor FAQ NVS vs JNJ Key Questions & Quantitative Answers

As of Nov 16, 2026, Johnson & Johnson (JNJ) captures the overall head-to-head institutional edge over Novartis AG (NVS) on higher Unified Composite conviction (43.8/100 HOLD vs. 41.5/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while NVS wins 3–2 across the 6-pillar growth and valuation breakdown. NVS trades at $161.59 (16.2x Forward P/E, 34.0% operating margin) versus JNJ at $284.71 (24.6x Forward P/E, 26.6% operating margin). Growth vs. Quality Trade-Off: JNJ earns the overall head-to-head edge with a stronger Unified Composite Score (43.8/100 HOLD vs. NVS 41.5/100 SELL) and -0.06β · 25% Vol risk profile, whereas NVS leads top-line expansion (+4.7% YoY revenue growth, 3.81x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

JNJ leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with JNJ at +5.9% YoY revenue growth and -95.9% YoY earnings growth on $99.3B TTM revenue (67.8% gross margin, 26.6% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $99.3B for JNJ. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 41.2% of Rev ($40.9B) (0 disclosures) for JNJ.

NVS screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas JNJ trades at 24.6x Forward P/E, 43.0x Trailing P/E, 3.16x PEG, and 7.2x EV/Revenue (19.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus JNJ (20.0% ROE) capital efficiency.

In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, JNJ carries 25.7% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.76x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.06β · 25% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.